Regulus Therapeutics Inc.

Competition to develop new treatments for autosomal dominant polycystic kidney disease (ADPKD) is ramping up, with Vertex ready to begin trials of a potential disease modifying treatment – but rival

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte

Sanofi has decided to abandon development of Regulus Therapeutics ’s lademirsen against a rare kidney disease after it failed to show benefit in an interim analysis. The San Diego-based biotech disc

Cell, gene and RNA therapies have been widely adopted by the major pharma players. While their growth is tremendous (52% CAGR up to 2026), they will only account for up to 7% of total market size by 2